H.R.4982 - Examining Opioid Treatment Infrastructure Act of 2016114th Congress (2015-2016)
|Sponsor:||Rep. Foster, Bill [D-IL-11] (Introduced 04/18/2016)|
|Committees:||House - Energy and Commerce | Senate - Health, Education, Labor, and Pensions|
|Committee Reports:||H. Rept. 114-560|
|Latest Action:||Senate - 05/12/2016 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Passed House
Here are the steps for Status of Legislation:
- Passed House
Text: H.R.4982 — 114th Congress (2015-2016)All Information (Except Text)
Text available as:
Referred in Senate (05/12/2016)
Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions
To direct the Comptroller General of the United States to evaluate and report on the in-patient and outpatient treatment capacity, availability, and needs of the United States.
This Act may be cited as the “Examining Opioid Treatment Infrastructure Act of 2016”.
Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation, and submit to Congress a report, of the inpatient and outpatient treatment capacity, availability, and needs of the United States, which shall include, to the extent data are available—
(1) the capacity of acute residential or inpatient detoxification programs;
(2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs;
(3) the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents;
(4) geographical differences of the availability of residential and outpatient treatment and recovery options for substance use disorders across the continuum of care;
(5) the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies;
(6) the number of patients in residential and specialty outpatient treatment services for substance use disorders;
(7) an assessment of the need for residential and outpatient treatment for substance use disorders across the continuum of care;
(8) the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined by section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
(9) the barriers (including technological barriers) at the Federal, State, and local levels to real-time reporting of de-identified information on drug overdoses and ways to overcome such barriers.
Passed the House of Representatives May 11, 2016.
|Attest:||karen l. haas,|